Synthetic dipeptide nootropic approved as a prescription drug in Russia; not FDA approved or recognized as a dietary supplement.
Proline-glycine dipeptide ester. Proposed cholinergic modulation and facilitation of BDNF / NGF expression. Active metabolite is cycloprolylglycine (CPG), an endogenous dipeptide.
Evidence summary in progress. See the citations section below for the underlying research papers.
No FDA label or editorial side-effect profile is on file for this compound yet. See the clinical trials and citations sections for study-reported safety data.
No documented drug interactions on file.
Not FDA approved. Approved in Russia. FDA has treated it as an unapproved drug; not a legal dietary-supplement ingredient.
Not available via 503A/503B compounding pharmacies.
Regulatory data last verified 4/19/2026
No indexed ClinicalTrials.gov studies for Noopept. This usually means the compound isn't being studied under an IND — check the citations section for peer-reviewed research instead.
Showing 20 of 30 papers. View all on PubMed →